P2RY12 and atrial fibrillation: Also, in the AUGUSTUS trial of patients with AF undergoing a PCI, the combination of a P2Y12 inhibitor with full-dose apixaban resulted in less bleeding and fewer hospitalisations without significant differences in the incidence of ischaemic events compared to regimens that included a VKA, acetylsalicylic acid, or both [11].